Making セルテクノロジー a Wholly Owned Subsidiary Through a Share Exchange and Establishing a Cell Therapy Platform
First written in FY2019-Q3. 2 of 9 entries say "Achieved", first in FY2019. Latest entry: FY2021-Q3.
0 other companies' latest entry also says "Achieved".
- FY2021-Q3AchievedAnnual report
「As a result, in connection with the postponement of the share transfer to Doujin Group Co., Ltd. announced by the Company on 30 September 2020, the transferee was changed to Reverse Co., Ltd., which was deemed to be the more suitable transferee. On 12 November 2020, the Company entered into a share transfer agreement with Reverse Co., Ltd. and completed the share transfer on the same day. As a result of the transfer, Cell Technology Co., Ltd. and its wholly owned subsidiary Remcare Co., Ltd. became subsidiaries of Reverse Co., Ltd.」
The transferee for Cell Technology and Remcare was changed from the Doujin Group to Reverse, the share transfer was completed on 12 November 2020, and the companies were excluded from the scope of consolidation. - FY2021-Q2SoftenedAnnual report
「The execution date of the share transfer was changed from the originally scheduled 30 September 2020 to 31 December 2020.」
The effective date of the transfer of Cell Technology shares to the Doujin Group was postponed from the date originally scheduled to 31 December 2020. - FY2021-Q1RestatedAnnual report
「At a Board of Directors meeting held on 10 July 2020, the Company resolved to transfer all issued shares of its consolidated subsidiary セルテクノロジー to 同仁グループ and entered into a share transfer agreement on the same date. The effective date of the transfer was scheduled for 30 September 2020.」
Reconfirms the plan to transfer all shares of セルテクノロジー to 同仁グループ and the scheduled effective date of 30 September 2020. - FY2020ReframedAnnual report
「In March 2020, the Company established the MCB manufacturing method. At a Board of Directors meeting held on 10 July 2020, the Company resolved to transfer all issued shares of its consolidated subsidiary セルテクノロジー to 同仁グループ and entered into a share transfer agreement on the same date.」
While establishing the MCB manufacturing method for the dental pulp stem cell-based cell therapy platform, the Company sold セルテクノロジー and reorganized its plans to focus management resources on the research and development of regenerative medicine products. - FY2020-Q3AdvancedAnnual report
「While advancing development of its existing pipeline, the Company held intensive discussions with universities and other research institutions on joint research using dental pulp stem cells to further expand the business. As a result, it entered into an industry-academia partnership agreement with Showa University in November 2019 to broaden the potential for commercializing regenerative medicine using dental pulp stem cells, and a four-party joint research agreement with the Tokyo Metropolitan Institute of Medical Science, Nagoya University and Tokyo Medical and Dental University in January 2020 to create a treatment for cerebral palsy using dental pulp stem cells.」
Following the acquisition of セルテクノロジー as a wholly owned subsidiary, the dental pulp stem cell-based cell therapy platform has progressed to an industry-academia partnership with Showa University and the conclusion of joint research agreements with multiple research institutions. - FY2020-Q2AdvancedAnnual report
「As part of business development using dental pulp stem cells, the Company steadily advanced the business by entering into a joint research and development agreement with ORTHOREBIRTH in May 2019 to create a treatment for cleft lip and palate, and separate joint research agreements with Showa University and Gifu Pharmaceutical University in September of the same year to create treatments for bone and eye diseases, respectively.」
Regarding the full acquisition of セルテクノロジー and the policy of establishing a cell therapy platform, the Company has moved into specific research into treatments for cleft lip and palate, bone diseases and eye diseases using dental pulp stem cells. - FY2020-Q1Cited as achievedAnnual report
「In April 2019, the Company made セルテクノロジー, which develops new medical technologies and regenerative medicine products using stem cells derived from dental pulp, a wholly owned subsidiary through a share exchange. Going forward, the Company will establish a cell therapy platform for its regenerative medicine business based on the cardiac stem cells of 日本再生医療 described above and セルテクノロジー's dental pulp stem cells, and pursue various business opportunities, including the development of new products and therapies.」
The filing reiterates the completed acquisition of セルテクノロジー as a wholly owned and consolidated subsidiary and continues the policy of establishing a cell therapy platform based on cardiac stem cells and dental pulp stem cells. - FY2019AchievedAnnual report
「Following approval at the Company's extraordinary general meeting of shareholders in March 2019, セルテクノロジー became a wholly owned subsidiary in April 2019. Going forward, the Company will establish a cell therapy platform for its regenerative medicine business based on the cardiac stem cells of 日本再生医療 described above and セルテクノロジー's dental pulp stem cells, and pursue various business opportunities, including the development of new products and therapies.」
Following approval at an extraordinary general meeting of shareholders, セルテクノロジー became a wholly owned subsidiary in April 2019, advancing the business to the stage of establishing a cell therapy platform. - FY2019-Q3First statedAnnual report
「In January 2019, the Company resolved to make セルテクノロジー, which develops new medical technologies and regenerative medicine products using dental pulp stem cells, a wholly owned subsidiary through a share exchange. By leveraging the company's dental pulp stem cell manufacturing technology to establish a cell therapy platform for the Company's regenerative medicine business, the Company will pursue various business opportunities, including the development of new products and therapies.」
On 17 January 2019, the Company entered into a share exchange agreement and resolved to make セルテクノロジー a wholly owned subsidiary. Subject to approval at an extraordinary general meeting of shareholders on 12 March 2019, the business combination was scheduled for 1 April 2019, with the Company scheduled to acquire a 100% voting interest by issuing 7,250,740 of its common shares. The Company aimed to establish a cell therapy platform by leveraging the company's dental pulp stem cell manufacturing technology, which is connected with approximately 2,200 dental clinics nationwide.